Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Breast Neoplasms 2Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, AIDS-Related 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Infiltrating Bladder Urothelial Carcinoma 1Hodgkin Disease 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Blast Crisis 1Amyloidosis 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

enzalutamide 33Abiraterone Acetate 28apalutamide 25Radiotherapy 25Prednisone 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 21Radiosurgery 19darolutamide 18Docetaxel 17acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Gonadotropin-Releasing Hormone 14gallium 68 PSMA-11 12Specimen Handling 12Goserelin 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Radiation 11bicalutamide 10abiraterone 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Standard of Care 8Nivolumab 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × pegfilgrastim × Clear all
NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Active not recruiting
44 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡